ADCT
- ADC Therapeutics SA
()
Overview
Company Summary
ADC Therapeutics SA (ADCT) is a company that specializes in the development of targeted antibody-drug conjugates (ADCs) for the treatment of various types of cancer. ADCs are innovative cancer drugs designed to specifically target cancer cells while minimizing damage to healthy cells and tissues.
ADCT's goal is to leverage the power of ADC technology to create highly potent and targeted therapies that have the potential to improve patient outcomes. They focus on developing ADCs for cancers that are difficult to treat or have limited treatment options.
The company utilizes proprietary technology platforms to create ADCs that consist of three main components: a monoclonal antibody that specifically recognizes cancer cells, a potent cytotoxic drug payload that kills the cancer cells upon internalization, and a linker molecule that connects the antibody and the payload.
By combining these components, ADCT's ADCs can selectively bind to cancer cells, allowing the cytotoxic drug to be delivered directly to the target cells. This approach enhances the drug's efficacy while reducing systemic toxicity, potentially leading to improved patient tolerability and overall treatment outcomes.
ADCT has a robust pipeline of ADC candidates at various stages of development, targeting a range of cancer indications. They conduct preclinical and clinical studies to evaluate the safety and efficacy of their ADCs and aim to advance promising candidates through the regulatory approval process to make them available to patients in need.
In summary, ADC Therapeutics SA is a biotechnology company dedicated to harnessing the potential of antibody-drug conjugates to develop targeted and effective therapies for cancer treatment.